Literature DB >> 15885660

Galphaq-coupled receptor signaling enhances adenylate cyclase type 6 activation.

Michael A Beazely1, Val J Watts.   

Abstract

Calcium signaling robustly inhibits AC6 activity in membrane preparations and in intact cells via capacitative calcium entry (CCE). However, the release of intracellular calcium has not been demonstrated to robustly alter AC6 signaling and activation of Galpha(q)-coupled receptors in tissues that express AC6 enhances cyclic AMP accumulation. To specifically examine the ability of Galpha(q)-coupled receptors to modulate AC6 signaling in intact cells, we used stably transfected HEK-AC6 cells. We demonstrate that AC6 activation is potentiated by activation of endogenous muscarinic receptors expressed in HEK293 cells. Muscarinic receptor activation failed to potentiate the activation of the closely related AC5 isoform. Expression of recombinant Galpha(q)-coupled muscarinic or serotonin receptors, or constitutively active Galpha(q), also potentiated drug-stimulated cyclic AMP accumulation in HEK-AC6 cells. Muscarinic receptor-mediated potentiation of AC6 activation was not due to activation of PKC or modulation of Galpha(i/o)-mediated inhibition of AC6. We demonstrate that calcium chelation or inhibition of calmodulin attenuates the effect of carbachol on AC6 activation. These data support the hypothesis that Galpha(q)-coupled receptor-mediated calcium signaling potentiates AC6 activation in intact cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15885660     DOI: 10.1016/j.bcp.2005.04.007

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  9 in total

1.  Characterization of vasopressin-responsive collecting duct adenylyl cyclases in the mouse.

Authors:  Kevin A Strait; Peter K Stricklett; Mark Chapman; Donald E Kohan
Journal:  Am J Physiol Renal Physiol       Date:  2009-12-02

2.  Developing skeletal muscle cells express functional muscarinic acetylcholine receptors coupled to different intracellular signaling systems.

Authors:  Ingrid Furlan; Rosely Oliveira Godinho
Journal:  Br J Pharmacol       Date:  2005-10       Impact factor: 8.739

Review 3.  Role of Collecting Duct Renin in the Pathogenesis of Hypertension.

Authors:  Alexis A Gonzalez; Lucienne S Lara; Minolfa C Prieto
Journal:  Curr Hypertens Rep       Date:  2017-08       Impact factor: 5.369

Review 4.  Unanticipated signaling events associated with cardiac adenylyl cyclase gene transfer.

Authors:  Mei Hua Gao; H Kirk Hammond
Journal:  J Mol Cell Cardiol       Date:  2011-02-23       Impact factor: 5.000

5.  The orphan receptor GPR139 signals via Gq/11 to oppose opioid effects.

Authors:  Hannah M Stoveken; Stefano Zucca; Ikuo Masuho; Brock Grill; Kirill A Martemyanov
Journal:  J Biol Chem       Date:  2020-06-23       Impact factor: 5.157

Review 6.  The cyclic AMP phenotype of fragile X and autism.

Authors:  Daniel J Kelley; Anita Bhattacharyya; Garet P Lahvis; Jerry C P Yin; Jim Malter; Richard J Davidson
Journal:  Neurosci Biobehav Rev       Date:  2008-06-17       Impact factor: 8.989

7.  PKC-α-dependent augmentation of cAMP and CREB phosphorylation mediates the angiotensin II stimulation of renin in the collecting duct.

Authors:  Alexis A Gonzalez; Liu Liu; Lucienne S Lara; Camille R T Bourgeois; Cristobal Ibaceta-Gonzalez; Nicolas Salinas-Parra; Venkateswara R Gogulamudi; Dale M Seth; Minolfa C Prieto
Journal:  Am J Physiol Renal Physiol       Date:  2015-08-12

8.  Vasopressin/V2 receptor stimulates renin synthesis in the collecting duct.

Authors:  Alexis A Gonzalez; Flavia Cifuentes-Araneda; Cristobal Ibaceta-Gonzalez; Alex Gonzalez-Vergara; Leonardo Zamora; Ricardo Henriquez; Carla B Rosales; L Gabriel Navar; Minolfa C Prieto
Journal:  Am J Physiol Renal Physiol       Date:  2015-11-25

9.  EP2 receptor mediated cAMP release is augmented by PGF 2 alpha activation of the FP receptor via the calcium-calmodulin pathway.

Authors:  A B Abera; K J Sales; R D Catalano; A A Katz; H N Jabbour
Journal:  Cell Signal       Date:  2009-09-25       Impact factor: 4.315

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.